Non-Habit Forming: Unlike Pregabalin, Ketamir-2 carries no known risk of dependence, making it safer for long-term use. Fewer ...
MIRA Pharmaceuticals (MIRA) announced that its novel oral ketamine analog, Ketamir-2, has shown greater pain relief compared to FDA-approved ...
MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a preclinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic ...
MIRA shares surge 10.3% after new preclinical data shows Ketamir-2 achieves 100% reversal of neuropathic pain. Ketamir-2 presentation set for October's Pain Therapeutics Summit, highlighting its ...
Benzinga (Video) on MSN19d
Small Changes… Big Effects! Breakthrough Therapies Are The Name Of The Game For This BiopharmaErez Aminov, CEO & Chairman of the Board, and Dr. Itzchak Angel, Chief Scientific Advisor for MIRA Pharmaceuticals MIRA, were ...
The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for ...
As of 6:35 PM GMT+2. Market Open. Conference presentation delivers preclinical results demonstrating Ketamir-2 achieves 100% reversal of neuropathic pain MIAMI, FL / ACCESSWIRE / September 27 ...
With the Click of a Button, Advisors Can Create the Optimal Tax Strategy for their Clients; Balancing Asset Location, Withdrawal, and Roth Conversion Strategies. SHELTON, CT / ACCESSWIRE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback